E-mail: sales@hlsw-bio.com
 
   
  +86-0510-85629785
   
  sales@hlsw-bio.com
info@hlsw-bio.com
   
  No.138,Mashan Meiliang Road,Hubin, Wuxi,Jiangsu Province,China
 
   
  News Your location: Home -News
 
   
   
Raw material drug profits continue to decline

Views:2784      origin:Administrator      Add time:2014-9-28
..........................................................................................................................................................................................................................................

According to the analysis showed that the labor letter department released the latest 2013 economic operation last year the pharmaceutical industry, pharmaceutical industry above Designated Size Enterprises to achieve the main business income of 2168160000000 yuan, a year-on-year growth of 17.9%, chemical raw material medicine grew 13.7%, for second consecutive years as the slowest sub industry growth.
On one side is the current situation of pile up in excess of requirement, excess production capacity of the industry, one side is the trade investigation came from other countries, "transformation" has become the inevitable choice of raw material medicine enterprise reverse the survival plight.
Raw material medicine industry downturn /
Public information display, the development of our country traditional bulk raw materials by penicillin, vitamin series and series of antipyretic analgesic category mainly. Due to lower technical threshold, a large number of competitors to bulk chemical raw material medicine.
With the last century 90's global raw material medicine industry transfer, in order to high pollution, high energy consumption and low cost price for promoting the development of our country, is the world's largest chemical raw material medicine production and export country, serious excess capacity leads to frequent price war. Among them, penicillin, vitamin C occupy more than 50% of international market share.
Chamber of Commerce vice president Xu Ming said in an interview with reporters Chinese medicines and health products import and export, China's traditional bulk raw material trade has experienced multiple difficulties, will be a long time in the downlink channel. "The bulk raw material industry excess capacity, coupled with the export demand to reduce, countries' impedance 'policy impact on antibiotic demand from developing countries, plus India, Mexico and other low price competition, production enterprises of raw material medicine must transition."
In addition, the raw material medicine in recent years were frequent in the international market suffered a "dual" survey. "The high price, is the anti monopoly; low prices, and anti dumping. Over the past few years, according to the survey Chinese API international trade increasing." Xu Mingru told reporters.
The Ministry released the latest data show, last year the chemical raw materials of China's manufacturing profits amounted to 28470000000 yuan, the profit rate is 7.45%, grow 0.02% compared to the same period, the industry average of 10.13%. Shanghai securities analyst believes that, due to industry overall supply and demand situation not to produce major change, the current listing Corporation revenue and profit growth, profit prospects of raw material medicine industry is still poor.
The reporter notices, dominated by products of vitamin E of weak market demand and competitive effect, Zhejiang medicine last year net profit fell 46.72%.








Prev:Raw material medicine serious excess capacity

Next:Raw material medicine in crossroads
       
  Add:No.138,Mashan Meiliang Road,Hubin, Wuxi,Jiangsu Province,China
Tel:+86-0510-85629785   Fax:+86-0510-85625359   E-mail:sales@hlsw-bio.com info@hlsw-bio.com
Copyright (c) Wuxi Helen Biotechnology Co., Ltd. All rights reserved    备案号:苏ICP备16043161号